Moderna Stock Price, News & Analysis

Moderna (Nasdaq: MRNA) has signed a long-term agreement with UNICEF to supply up to 34 million doses of its COVID-19 vaccine in Q4 2021 and 466 million doses in 2022. The doses will be provided at the company's lowest tiered price, supporting global vaccine access through the COVAX Facility. CEO Stéphane Bancel emphasized the commitment to combating the pandemic. Additionally, the WHO granted Emergency Use Listing for the vaccine, enhancing its distribution potential.

Moderna (Nasdaq: MRNA) announced a new agreement with Lonza to enhance drug substance manufacturing, enabling the supply of an additional 300 million doses of its updated COVID-19 booster vaccine candidate annually at a 50 µg dose. This builds on previous investments, allowing for a total of 600 million doses per year from EU production. The company is ramping up production capacity in collaboration with multiple partners, targeting completion by year-end 2021 to meet global demand for its vaccines.

Moderna (Nasdaq: MRNA) has entered a partnership with Thermo Fisher Scientific (NYSE: TMO) for sterile manufacturing services for its COVID-19 vaccine. This collaboration will utilize Thermo Fisher's Greenville, NC facility for fill/finish, labeling, and packaging, enabling the production of hundreds of millions of vaccine doses starting Q3 2021. Moderna's Chief Technical Operations and Quality Officer expressed satisfaction in expanding the relationship to enhance manufacturing capabilities. This agreement highlights Moderna's continued efforts to scale vaccine production amidst the ongoing pandemic.

Moderna (Nasdaq: MRNA) has initiated the rolling submission process for a Biologics License Application (BLA) for its mRNA COVID-19 vaccine aimed at individuals 18 and older. The request includes a Priority Review, with data from ongoing Phase 3 studies being submitted periodically. The vaccine is currently authorized under Emergency Use Authorization (EUA) and has administered over 124 million doses in the U.S. since its EUA grant in December 2020. Moderna continues to innovate with variant-specific booster candidates as part of its COVID-19 response.

Moderna (Nasdaq: MRNA) has announced its participation in two upcoming virtual investor conferences. The Jefferies Virtual Healthcare Conference will take place on June 3, 2021, at 10:00 a.m. ET, followed by the Goldman Sachs 42nd Annual Healthcare Conference on June 9, 2021, at 8:00 a.m. ET. Live webcasts of both events will be accessible on the Investors section of Moderna's website, and replays will be available for 30 days post-event. Moderna has evolved significantly in its 10-year history, establishing a strong clinical portfolio and a robust mRNA platform for various diseases.

Moderna, Inc. (Nasdaq: MRNA) held its fourth annual Science Day to showcase developments in mRNA therapeutics and vaccines. The event highlights 24 mRNA programs, with 14 in clinical studies, and focuses on the advancements in mRNA delivery, particularly targeting hematopoietic stem cells, and optimizing mRNA engineering for enhanced protein expression. The company is also leveraging AI to address SARS-CoV-2 variants. These efforts underscore Moderna's continuous commitment to innovation in utilizing mRNA for therapeutic purposes.

Moderna (Nasdaq: MRNA) announced that its Phase 2/3 study of the COVID-19 vaccine (mRNA-1273) in adolescents (ages 12-17) successfully met its primary immunogenicity endpoint. The study, enrolling over 3,700 participants, showed no COVID-19 cases in the vaccine group after two doses, achieving 100% efficacy under adult case definitions. Additionally, a 93% efficacy was noted in seronegative participants using a secondary CDC definition after the first dose. The safety profile was consistent with adult studies, prompting plans to submit findings for global regulatory approval in early June.

Moderna (Nasdaq:MRNA) has expanded its collaboration with Aldevron, enhancing support for both the Moderna COVID-19 Vaccine and its clinical development pipeline. Aldevron will supply plasmid DNA, which is essential for generating the mRNA vaccines. This partnership, spanning nearly a decade, aims to leverage Aldevron's manufacturing capabilities, including a newly expanded GMP facility in Fargo, North Dakota. Moderna continues to work on a diverse range of programs, including various therapeutics and vaccines, while maintaining strategic alliances to maximize their operational efficiency.

Moderna (Nasdaq: MRNA) has entered into a Manufacturing Services and Supply Agreement with Samsung Biologics to conduct large-scale commercial fill-finish manufacturing of its COVID-19 vaccine, mRNA-1273. The technology transfer will start immediately at Samsung's Incheon facility, aiming to produce hundreds of millions of doses for markets outside the U.S. by Q3 2021. This partnership enhances Moderna's manufacturing capacity, crucial during the ongoing pandemic. Both companies emphasize the urgency in supplying the vaccine globally.